Transcutaneous Spinal Cord Stimulation Enables Recovery of Walking in Children with Acute Flaccid Myelitis Go to source) ...

Nevro Corp. (NYSE: NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the ...

This systematic review and network meta-analysis found that spinal cord stimulation therapies for treatment of chronic pain in back and/or lower extremities were associated with greater improvements ...

This systematic review and network meta-analysis found that spinal cord stimulation therapies for treatment of chronic pain ...

The global spinal cord stimulators market is on a robust growth trajectory, poised to reach an impressive valuation of USD 5,441.4 million by 2033. Currently valued at USD 2,702.7 million in 2023, the ...

US-based device company Nevro has secured market authorisation from the European Union (EU) for its HFX iQ spinal cord ...

Nevro (NYSE:NVRO) announced today that it received CE mark in Europe for its HFX iQ spinal cord stimulation (SCS) system.

Nevro's HFX iQ spinal cord stimulator earned the European Union's CE mark, the company said Nov. 12.

HFX iQ is the first and only spinal cord stimulation (SCS) system integrating high-frequency SCS landmark evidence with cloud ...

Data from the SENZA-PDN trial showed 10 kHz SCS yielded long-term, clinically meaningful reductions in HbA1c and weight in patients with PDN and T2D.